A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants
Public ClinicalTrials.gov record NCT07011797. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: * To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo. * To compare the changes of effects in weight and weight-related indicators at the visit time points. * To evaluate the tolerability and safety of different doses of CX11 tablets in overweight/obese participants. * To assess the pharmacokinetics (PK) of different doses of CX11 tablets in overweight/obese participants. Overweight/obese participants who are successfully screened will be randomized in a 1:1:1:1:1 ratio to different doses of CX11 tablets or placebo. All participants will enter a 2-week follow-up period after 36 weeks of treatment for safety observation.
Study identification
- NCT ID
- NCT07011797
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 250 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 16, 2025
- Primary completion
- Mar 22, 2026
- Completion
- Apr 8, 2026
- Last update posted
- May 27, 2026
2025 – 2026
United States locations
- U.S. sites
- 17
- U.S. states
- 8
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| AES - DRS - Synexus Clinical Research US, Inc. - Phoenix Central | Phoenix | Arizona | 85020-4327 | — |
| 310 Clinical Research - Alliance Clinical - Los Angeles | Inglewood | California | 90301 | — |
| Acclaim Clinical Research - Alliance Clinical - San Diego | San Diego | California | 92120 | — |
| Angels Clinical Research Institute - Miami | Doral | Florida | 33122-1713 | — |
| AES - DRS - Optimal Research Florida - Melbourne | Melbourne | Florida | 32934-8172 | — |
| Angels Clinical Research Institute | Miami | Florida | 33126 | — |
| Palm Springs Community Health Center | Miami Lakes | Florida | 33014-2266 | — |
| Oceanic Research Group, LLC | North Miami Beach | Florida | 33169 | — |
| Privia Medical Group Georgia, LLC - Savannah - Javara - PPDS | Savannah | Georgia | 31406-3928 | — |
| Privia Medical Group Georgia, LLC - Thomasville - Javara - PPDS | Thomasville | Georgia | 31792-6618 | — |
| Velocity Clinical Research - Valparaiso (Buynak Clinical Research) - PPDS | Valparaiso | Indiana | 46383 | — |
| Mankato Clinic - East Main Street - Javara - PPDS | Mankato | Minnesota | 56001 | — |
| Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS | Cincinnati | Ohio | 45246-2316 | — |
| Velocity Clinical Research - Dallas - PPDS | Dallas | Texas | 75230 | — |
| Epic Clinical Research - Alliance Clinical - Lewisville | Lewisville | Texas | 75057 | — |
| AES - DRS - Synexus Clinical Research US, Inc. - San Antonio | San Antonio | Texas | 78229 | — |
| Flourish Research - San Antonio - PPDS | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07011797, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 27, 2026 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07011797 live on ClinicalTrials.gov.